Background and Aims: Small-cell lung cancer (SCLC) is an
Background and Aims: Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with high malignancy, frequent metastases and poor prognosis. SCLC patients are relatively sensitive to radiotherapy and chemotherapy, which are mainly therapies in the clinical of SCLC. However, the puzzle in the therapy was the rapid resistance of tumor cells against chemotherapy and the failure of second-line chemotherapy. The purpose of this study was to use the method of precision medical detecting the genes related to SCLC and the key molecular markers that are suitable for the curative effect of chemotherapy, resulting in realize the molecular prediction of small cell lung cancer.
Methods: 24 patients with first-line treatment of SCLC receiving standard chemotherapy (EP) were included, whom were reviewed and categorized into two groups: Disease progression (PD) and Partial remission (PR). Tumor tissues DNA of the patients were detected by using specific target gene capture sequencing technology to discover the gene variation in SCLC and SCLC chemotherapy curative effect related genes were analyzed by bioinformatics methods.
Results: TP53,CYP2C19,ZFHX3, BCL2 are the common gene mutations in Chinese SCLC patient population; Common Genes for Copy number variations (CNV) in small cell lung cancer in China: FDPS,SOX2, MAP2K2,PSMA8,MALAT1; The comparative analysis in patients with CNV between PD and PR groups showed EGFR gene copy number variation was detected only in the PR group, and there was a significant difference between the two groups (P < 0.05, Fisher test); The tumor tissue DNA somatic cells single nucleotide variants (SNV), genotypes associated with first-line chemotherapy (EP), Tumor Mutational Burden (TMB) and Copy number instability (CNI) of tumor tissues showed no significant difference between two groups.
Conclusion: There was a significant EGFR gene copy number variation difference between the PD and PR groups. The SNV, TMB and CNI of tumor tissues showed no significant difference between two groups. The Japanese red Cross Nagasaki Genbaku Hospital, Japan Background and Aims: Nivolumab which was approved in December 2015 in Japan, is a PD-1 immune check point inhibitor antibody that disrupts PD-1 mediated signalling and restores antitumor immunity. It showed survival benefit with improved safety profile compared to Docetaxel treatment in advanced non-small-cell lung cancer, however, some immune-related adverse events (irAE) including lung injury can be severe and risk factors of irAE are not identified.
Methods: Ninety three consecutive advanced non-small-cell lung cancer patients treated with nivolumab who attended Nagasaki University Hospital and affiliated hospitals between January 2016 and December 2017 were enrolled. We analyzed these patients' background, tumor type, performance status, tumor response and treatment related adverse events retrospectively.
Results: The number of men and women are 71 and 22, and median age is 67 (31-89). The number of patients of performance status 0,1,2 and 3 is 20 (21.5%), 56 (60.2%), 15 (16.1%) and 2 (2.1%) respectively. The numbers of Squamous cell carcinoma (Sq) and non-Squamous cell carcinoma (non-Sq) are 28(30.1%) and 65(69.9%). Response rate is 27.3%. (CR 0%, PR 27.3%). Median-progression free survival of Sq and non-Sq is 66 and 127 days (P = 0.0667). Grade3-5 IrAE occurred in 16 (7.4%) patients and Grade5 IrAE occurred in 3 (3.3%). Additionally, grade 3-5 adverse events of lung injury occurred in 8 (8.6%) patients.
The proportion of each lung injury patterns were as follow: OP, NSIP, HP and AIP/ARDS is 62.5, 12.5, 0 and 25%. Patients with OP pattern were successfully treated with corticosteroids otherwise, patients with AIP/ARDS pattern have poor prognosis. All lung injury events occurred within 16 weeks, especially AIP pattern occurred within 4 weeks. All patients with lung injury were men and have smoking history.
Conclusion:
There was no significant difference for tumor response and treatment related adverse events compared to previous study however, the incidence of lung injury was a little higher than previous study. ALK fusion gene were analyzed using reverse transcription polymerase chain reaction and BIM deletion was checked by polymerase chain reaction and fragment length analysis.
Results: During December 2010-December 2017, there were 54 patients with known ALK variants received crizotinib for advanced NSCLC. 30 of them had successful BIM deletion analysis. Patients with ALK variant 2 had a trend for longer crizotinib progression free survival (PFS) (median, not reached vs 6.1 months, 95% confidence interval [CI], 1.15 -9.46, P = 0.10 by Log-rank test). Multivariate Cox regression analysis found previous anticancer therapy (adjusted hazard ratio [aHR] 1.37,
